A long-term study of the safety of rituxan in patients with rheumatoid arthritis after an inadequate response to previous Anti-TNF [tumour necrosis factor] therapy (SUNSTONE).
Phase of Trial: Phase IV
Latest Information Update: 11 Jun 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms SUNSTONE
- Sponsors Genentech
- 26 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Dec 2012 Planned End Date added 1 Dec 2013 as reported by ClinicalTrials.gov record.
- 12 Nov 2010 Additional lead investigator identified as reported by ClinicalTrials.gov.